Corrigendum to “Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial” [The Breast 78 (2004) 103795]
Karolina Larsson F, Jamila Adra, Leif Klint, Barbro Linderholm
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Treatment and Pharmacology · Advanced Breast Cancer Therapies · Breast Cancer Treatment Studies
The authors wish to correct an error in the reported median progression-free survival (PFS) in our study. Due to a misunderstanding, the date of death was mistakenly used instead of the date of progression. As a result, the originally reported median PFS of 16 months is incorrect. The correct median PFS is 8.5 months as indicated in the updated Fig. 1 and the Graphical Abstract.
As PFS was only a secondary outcome, we believe this correction does not impact the main conclusions of the study.
The authors would also like to acknowledge Ahmet Akdeve at Statistikkonsulterna Väst AB for their prompt assistance in correcting the statistical error.
We sincerely apologize for any confusion or inconvenience this may have caused.Fig. 1PFS in a cohort of 40 patients with metastatic breast cancer treated with metronomic chemotherapy with capecitabine and cyclophosphamide.Fig. 1
Graphical abstract
Image 1